Peripheral blood stem cell allograft rejection mediated by CD4(+) T lymphocytes recognizing a single mismatch at HLA-DP beta 1*0901

Blood. 2001 Aug 15;98(4):1122-6. doi: 10.1182/blood.v98.4.1122.

Abstract

Little is known about the molecular characteristics of alloantigens recognized by alloreactive T cells mediating hematologic stem cell graft rejection. In particular, it has never been shown that such alloantigens can be encoded by HLA-DP beta alleles. Indeed, matching for HLA-DP antigens is generally not considered to be of functional importance for the outcome of allogeneic bone marrow or peripheral blood stem cell transplantation. In this study, a case of peripheral blood stem cell allograft rejection was investigated in which the patient and donor differed for a single mismatch at HLA-DP in the rejection direction. Patient-derived T lymphocytes circulating at the time of rejection showed direct ex vivo cytotoxic activity against donor-derived B-lymphoblastoid cells as well as other HLA-DP beta 1*0901--expressing targets. The presence of HLA-DP beta 1*0901--specific effectors in vivo was further confirmed by in vitro stimulation experiments. CD4(+) T-cell lines and clones with specific cytotoxic activity against HLA-DP beta 1*0901--expressing targets including donor B-lymphoblastoid cells were generated both by nonspecific and by donor-specific in vitro stimulation. Taken together, these data demonstrate that HLA-DP can be the target antigen of cytotoxic CD4(+) T lymphocytes involved in peripheral blood stem cell allograft rejection. (Blood. 2001;98:1122-1126)

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Donors
  • CD4-Positive T-Lymphocytes / immunology*
  • Fathers
  • Female
  • Graft Rejection / chemically induced
  • Graft Rejection / immunology*
  • HLA-DP Antigens / immunology
  • HLA-DP Antigens / pharmacology*
  • HLA-DP beta-Chains
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cells / immunology*
  • Histocompatibility / drug effects*
  • Histocompatibility / immunology
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Male
  • Middle Aged
  • T-Lymphocytes, Cytotoxic / immunology
  • Transplantation, Homologous / adverse effects*

Substances

  • HLA-DP Antigens
  • HLA-DP beta-Chains
  • HLA-DPB1*09:01 antigen